Christine Livek
Family Medicine · Eldon, MONPI 1194758011
Payments from drug & device makers
Across 172 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- Sunovion Pharmaceuticals Inc.$319
- Novo Nordisk$231
- Lilly USA, LLC$196
- Amgen$153
- Abbott$145
- plus $1K from 32 others
What the payments were for
- Consulting fees$211%
- Food & beverage$2,82797%
- Education$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $396 |
| Sunovion Pharmaceuticals Inc. | 16 | $319 |
| Novo Nordisk | 12 | $231 |
| Lilly USA, LLC | 13 | $196 |
| Amgen | 10 | $153 |
| Abbott | 7 | $145 |
| Novartis | 8 | $135 |
| Merck | 8 | $129 |
| AstraZeneca | 9 | $120 |
| Lundbeck LLC | 3 | $102 |
| Pfizer | 7 | $101 |
| Johnson & Johnson | 6 | $80 |
| Boehringer Ingelheim | 5 | $78 |
| Shield Therapeutics Inc | 2 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $65 |
| GSK | 4 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $25 |
| SK Life Science, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| UCB, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Z-medica, LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Bayer | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
How this compares
$2,925 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,853 | $533,438 |
| XareltoRivaroxaban | 579 | $160,701 |
| OzempicSemaglutide | 146 | $151,488 |
| JardianceEmpagliflozin | 479 | $136,288 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 377 | $86,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $80,524 |
| Invega SustennaPaliperidone Palmitate | 28 | $74,079 |
| Humira PenAdalimumab | 11 | $71,275 |
| FarxigaDapagliflozin Propanediol | 195 | $69,543 |
| NuplazidPimavanserin Tartrate | 26 | $64,723 |
| TrulicityDulaglutide | 117 | $61,855 |
| MyrbetriqMirabegron | 248 | $60,100 |
| RexultiBrexpiprazole | 66 | $58,406 |
| BriviactBrivaracetam | 69 | $51,285 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $50,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $101 | $533,4381,853 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $80 | $234,780607 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $78 | $184,189543 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $51 | $158,146347 claims |
| Novo NordiskOzempic | $231 | $151,488146 claims |
| AbbVieVraylar, Creon, Linzess | $396 | $90,91095 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $120 | $90,604235 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $196 | $82,053133 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $60,100248 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $58,40666 claims |
| UCB, Inc.Briviact | $21 | $51,28569 claims |
| MerckJanuvia | $129 | $48,096101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Eldon
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.